Your browser doesn't support javascript.
loading
Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.
Philipson, Rebecca G; Romero, Tahmineh; Wong, Jessica K; Stish, Bradley J; Dess, Robert T; Spratt, Daniel E; Pilar, Avinash; Reddy, Chandana; Wedde, Trude B; Lilleby, Wolfgang A; Fiano, Ryan; Merrick, Gregory S; Stock, Richard G; Demanes, D Jeffrey; Moran, Brian J; Braccioforte, Michelle; Tran, Phuoc T; Martin, Santiago; Martinez-Monge, Rafael; Krauss, Daniel J; Abu-Isa, Eyad I; Valle, Luca; Chong, Natalie; Pisansky, Thomas M; Choo, C Richard; Song, Daniel Y; Greco, Stephen; Deville, Curtiland; McNutt, Todd; DeWeese, Theodore L; Ross, Ashley E; Ciezki, Jay P; Tilki, Derya; Karnes, R Jeffrey; Klein, Eric A; Tosoian, Jeffrey J; Boutros, Paul C; Nickols, Nicholas G; Bhat, Prashant; Shabsovich, David; Juarez, Jesus E; Kupelian, Patrick A; Rettig, Matthew B; Berlin, Alejandro; Tward, Jonathan D; Davis, Brian J; Reiter, Robert E; Steinberg, Michael L; Elashoff, David; Horwitz, Eric M.
Afiliação
  • Philipson RG; Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
  • Romero T; UCLA Division of General Internal Medicine and Health Services Research, Los Angeles, CA, USA.
  • Wong JK; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Stish BJ; Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
  • Dess RT; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
  • Spratt DE; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
  • Pilar A; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada.
  • Reddy C; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Wedde TB; Oslo University Hospital, Oslo, Norway.
  • Lilleby WA; Oslo University Hospital, Oslo, Norway.
  • Fiano R; Schiffler Cancer Center, Wheeling Hospital, Wheeling Jesuit University, Wheeling, WV, USA.
  • Merrick GS; Schiffler Cancer Center, Wheeling Hospital, Wheeling Jesuit University, Wheeling, WV, USA.
  • Stock RG; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Demanes DJ; California Endocurietherapy Cancer Center, Oakland, CA, USA.
  • Moran BJ; Chicago Prostate Cancer Center, Westmont, IL, USA.
  • Braccioforte M; Chicago Prostate Cancer Center, Westmont, IL, USA.
  • Tran PT; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Martin S; Department of Radiation Oncology, Clínica Universidad de Navarra and Program in Solid Tumors, CIMA- University of Navarra, Pamplona, Spain.
  • Martinez-Monge R; Department of Radiation Oncology, Clínica Universidad de Navarra and Program in Solid Tumors, CIMA- University of Navarra, Pamplona, Spain.
  • Krauss DJ; Oakland University William Beaumont School of Medicine, Royal Oak, MI, USA.
  • Abu-Isa EI; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
  • Valle L; Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
  • Chong N; Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
  • Pisansky TM; Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
  • Choo CR; Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
  • Song DY; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Greco S; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Deville C; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • McNutt T; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • DeWeese TL; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Ross AE; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Ciezki JP; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Tilki D; Department of Urology and Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Karnes RJ; Department of Urology, Mayo Clinic, Rochester, MN, USA.
  • Klein EA; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Tosoian JJ; Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Boutros PC; Department of Urology, University of California Los Angeles, Los Angeles, CA, USA.
  • Nickols NG; Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA; Department of Radiation Oncology, West Los Angeles Veterans Health Administration, Los Angeles, CA, USA.
  • Bhat P; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
  • Shabsovich D; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
  • Juarez JE; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
  • Kupelian PA; Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
  • Rettig MB; Department of Medical Oncology, University of California Los Angeles, Los Angeles, CA, USA; Department of Medical Oncology, West Los Angeles Veterans Health Administration, Los Angeles, CA, USA.
  • Berlin A; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.
  • Tward JD; Department of Radiotherapy Oncology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.
  • Davis BJ; Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
  • Reiter RE; Department of Urology, University of California Los Angeles, Los Angeles, CA, USA.
  • Steinberg ML; Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
  • Elashoff D; UCLA Division of General Internal Medicine and Health Services Research, Los Angeles, CA, USA.
  • Horwitz EM; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Eur Urol ; 80(2): 142-146, 2021 08.
Article em En | MEDLINE | ID: mdl-33985797
ABSTRACT
The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecurrent HRPCa who previously received either external beam radiation therapy (EBRT, n = 654, 67%) or EBRT + brachytherapy (EBRT + BT, n = 324, 33%) across 15 institutions from 1997 to 2015. In men who did not die, median follow-up after treatment was 8.9 yr and median follow-up after biochemical recurrence (BCR) was 3.7 yr. Local and systemic therapy salvage, respectively, were delivered to 21 and 390 men after EBRT, and eight and 103 men after EBRT + BT. Overall, 435 men developed DM, and 248 were detected within 1 yr of BCR. Measured from time of recurrence, 5-yr DM rates were 50% and 34% after EBRT and EBRT + BT, respectively. Measured from BCR, 5-yr PCSM rates were 27% and 29%, respectively. Interval to BCR was independently associated with DM (p < 0.001) and PCSM (p < 0.001). These data suggest that radiorecurrent HRPCa has an aggressive natural history and that DM is clinically evident early after BCR. These findings underscore the importance of further investigations into upfront risk assessment and prompt systemic evaluation upon recurrence in HRPCa. PATIENT

SUMMARY:

High-risk prostate cancer that recurs after radiation therapy is an aggressive disease entity and spreads to other parts of the body (metastases). Some 60% of metastases occur within 1 yr. Approximately 30% of these patients die from their prostate cancer.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Braquiterapia Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Eur Urol Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Braquiterapia Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Eur Urol Ano de publicação: 2021 Tipo de documento: Article